2016 |
Almut Koch |
The worldwide challenge of antibiotic resistance. Strategies in Europe and USA from a regulatory point of view |
|
|
2016 |
Mariana Lagos Quintana |
Oligonucleotide-based Therapeutics, Development and Regulatory Challenges *** |
|
|
2016 |
Katrin Lambrecht |
Pyrrolizidine alkaloids - Impact of the public statements made by EMA and national health authorities on the pharmaceutical industry *** |
|
|
2016 |
Martina Luh |
Data integrity: Presentation of Measuring values in Module 3: Challenges for Regulatory CMC |
|
|
2016 |
Dr. Julia Katharina Mack |
Revision of Council Directive 90/167/EEC – current and future legal situation regarding medicated feed in the European Union as compared to the United States of America and Canada *** |
|
|
2016 |
Dr. Qian Mao |
Breakthrough Therapy Designation: Challenges and Opportunities for Innovative Drug Development – A Three-Year Review after PDUFA V *** |
|
|
2016 |
Juliane Merz |
Investigation on Melatonin as a Substance: A Closer Consideration of Differences and Similarities in the Legal Principles Applicable to Melatonin Containing Products at the International, European and National Level - Including a potential regulatory strategy to obtain a marketing authorisation for Germany |
|
|
2016 |
Christiane Metje |
Benefits and success of outsourcing in DRA |
|
|
2016 |
Dr. Caroline Mörler |
Produktinformationen in Deutschland: Welche europäischen sowie nationalen Verfahren und gesetzlichen Vorgaben nehmen Einfluss auf die Gestaltung von Fach- und Gebrauchsinformationen - eine Übersichtsarbeit |
|
|
2016 |
Dr. Robert Mühlbacher |
Diversity of regulatory requirements for the approval of biosimilars in the LATAM region: Comparison of the WHO guidance with the available guidelines/regulations in Chile, Brazil and Colombia *** |
|
|
2016 |
Kathrin Mundt |
National piloting activities in preparation of the new Clinical Trials Regulation Regulation (EU) No 536/2014 *** |
|
|
2016 |
Dr. Francois-Xavier Orveillon |
Status, challenges and regulatory framework for the development and registration of virus vectored vaccines in Europe |
|
|
2016 |
Dr. Julian Paesler |
Contraception in adolescents - regulatory considerations *** |
|
|
2016 |
Dr. Andrea Rohrauer-Scherr |
Benefit Assessment and Indication in Marketing Authorisation - Relevance for and Impact on Paediatric Research, Pricing, Reimbursement, Medical Therapy and Advertising *** |
|
|
2016 |
Gianluca Ronzoni |
Technical Regulatory change assessments for worldwide approved medicinal products - complexities in a regulatory non-harmonized and dynamically evolving environment |
|
|
2016 |
Ellen Scheibe |
The issue of extrapolation of indications in the registration of biosimilars *** |
|
|
2016 |
Dr. Brita Schulze |
Different Salts of a Drug Substance - Comparison of Regulatory Pathways in the EU and USA *** |
|
|
2016 |
Dr. Volker Spehr |
Virulence factor inhibition, a novel approach to treat life-threatening bacterial infections: Challenges for industry, legislation, and agencies *** |
|
|
2016 |
Till Teschke |
Changes in the regulatory assessment of manufacturing process validation *** |
|
|
2016 |
Anna Touhidi |
The Double Edged Regulation of Liquid Chemical Germicides Used in Healthcare Settings. The Burden of a Joint Jurisdiction, Demarcation of Categories and Regulatory Requirements in the United States of America *** |
|
|